4.8 Article

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function

Journal

MOLECULAR CELL
Volume 58, Issue 6, Pages 925-934

Publisher

CELL PRESS
DOI: 10.1016/j.molcel.2015.04.016

Keywords

-

Funding

  1. NCI NIH HHS [R01 CA099996] Funding Source: Medline

Ask authors/readers for more resources

Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were recently shown to have potential clinical impact in a number of disease settings, particularly as related to cancer therapy, treatment for cardiovascular dysfunction, and suppression of inflammation. The molecular basis for PARP1 inhibitor function is complex, and appears to depend on the dual roles of PARP1 in DNA damage repair and transcriptional regulation. Here, the mechanisms by which PARP-1 inhibitors elicit clinical response are discussed, and strategies for translating the preclinical elucidation of PARP-1 function into advances in disease management are reviewed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available